Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 17, 2024, titled "Zydus receives Final Approvals from the USFDA for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg".
Press Release Jan 17 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approvals from the USFDA for Pimavanserin Capsules and Tablets. These products are indicated for treating hallucinations and delusions associated with Parkinson disease psychosis. The manufacturing will take place at the company's facility in Ahmedabad SEZ, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 22 2023
- Press Release Dec 16 2023
- Press Release Dec 15 2023
- Press Release Dec 14 2023
- Press Release Dec 11 2023
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Jan 19 2024
- Press Release Jan 25 2024
- Zydus Lifesciences Limited Press Release Jan 30 2024
- Press Release Feb 08 2024
- Press Release Feb 09 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences